Vaxart Hosting Key Opinion Leader Panel Call for Investors - Nov 16, 2020
Title: An Oral Tablet Vaccine – A Potential Global Solution to COVID-19 and Norovirus
COVID-19: Immunity & Immunological Memory
Norovirus: Disease Burden & Prevention. The Current Status of Vaccine Development
Mucosal Immunity and the importance of secretory IgA
Administration and Logistical Advantages of a Pill
Investor Panel Being Held on Thursday, November 19th @ 12pm Eastern Time
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that it will host a Key Opinion Leader (KOL) panel for investors entitled “An Oral Tablet Vaccine – A Potential Global Solution to COVID-19 and Norovirus?” on Thursday, November 19, 2020 at 12pm Eastern Time.
These KOLs will provide their perspectives on the COVID-19 and Norovirus disease landscapes, highlighting the tracking of immune responses post-infection, and on preventing infection and disease spread. Vaxart's management team will also provide an update on its first-in-class oral tablet vaccine platform as well as Vaxart’s Phase 1 trial for Norovirus and results from preclinical studies on Vaxart’s investigational COVID-19 vaccine.
- Dr. Pepper on the importance of immunological memory and quick responses to a pathogen, and how it relates to COVID-19.
- Dr. Vinjé to speak on Norovirus incidence, outbreak surveillance, and global vaccine developments to date.
- Dr. Sean Tucker, Ph.D. (Vaxart) to discuss VXA-CoV2-1, Vaxart’s oral investigational tablet COVID-19 vaccine. What the pre-clinical data show and what’s next. He will also discuss Vaxart’s Norovirus oral vaccine program.
Both KOLs and the Vaxart management team will be available for Q&A following the formal presentation.
Marion Pepper, Ph.D. is an internationally recognized immunologist. She is an Associate Professor in the Department of Immunology at the University of Washington School of Medicine. Her research focuses on how protection from disease, known as immunity, develops. Specifically, her lab strives to understand how specialized immune cells, called T cells and B cells, respond to various types of infection or allergic inflammation in an effort to make better vaccines and therapeutics. Her published work has been cited over 4,000 times, and she is on the editorial board of several top tier journals, including Cell Reports and Immunity. She has served as a scientific consultant for multiple for profit companies focused on immunotherapeutics and is a member of the scientific advisory board of Neoleukin Therapeutics. Dr. Pepper has presented her work at over 70 national and international universities and conferences. In 2017, she was named a recipient of the prestigious Buroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease Award. In addition to her research, she is also passionate about communicating science to others and teaches undergraduate, medical school and graduate level courses. She is a strong advocate for women in science, and recently contributed an essay to Nature Immunology on the topic.
Jan Vinjé, Ph.D., is head of the National Calicivirus Laboratory and Director of CaliciNet in the Division of Viral Diseases at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. Dr. Vinjé received his Ph.D. at the University of Utrecht, the Netherlands, in 1999. After completing a postdoctoral fellowship and an appointment as research assistant professor at the University of North Carolina in Chapel Hill, he joined CDC in 2006. Over the past 10 years, he has served on program advisory committees from several European research projects (FP6, FP7). He has served as technical expert on the norovirus subcommittee of the National Advisory Committee on Microbiological Criteria for Foods and is the chair of the International Committee on Taxonomy of Viruses study groups on Caliciviridae. He is currently a member of the editorial board of the Journal of Clinical Microbiology and associate editor of the journal Food and Environmental Virology, and he serves as an ad hoc reviewer for multiple high-impact journals. Dr. Vinjé has published over 200 peer-reviewed publications and several book chapters. His research interests include all aspects of viral gastrointestinal disease, including detection, characterization, and prevention and control of norovirus infections.
Vaxart is a clinical-stage biotechnology company focused on developing oral tablet vaccines designed to generate mucosal and systemic immune responses that protect against a wide range of infectious diseases and have the potential to provide sterilizing immunity for diseases such as COVID-19. Vaxart believes that a room temperature stable tablet is easier to distribute, store and administer than injectable vaccines and may provide a significantly faster response to a pandemic than injectable vaccines, enabling a greater portion of the population to be protected. Vaxart’s development programs include oral tablet vaccines that are designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). For more information, please visit www.vaxart.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Vaxart’s strategy, prospects, plans and objectives, results from pre-clinical and clinical trials, commercialization agreements and licenses, beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as “should,” “believe,” “could,” “potential,” “will,” “expected,” “plan” and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to Vaxart’s ability to develop and commercialize its product candidates, and preclinical and clinical results and trial data (including plans with respect to the COVID-19 vaccine product candidates); expectations relating to Vaxart’s relationship with Emergent, KindredBio and AMS including their ability to produce bulk cGMP vaccines and the timing thereof; and Vaxart’s expectations with respect to the important advantages it believes its oral vaccine platform can offer over injectable alternatives, particularly for mucosal pathogens such as norovirus, flu and RSV, as well as coronaviruses such as SARS, MERS and SARS-CoV-2. Vaxart may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect the availability or commercial potential of any product candidate, including the possibility that Vaxart’s product candidates may not be approved by the FDA or non-U.S. regulatory authorities; that, even if approved by the FDA or non-U.S. regulatory authorities, Vaxart’s product candidates may not achieve broad market acceptance; that a Vaxart collaborator may not attain development and commercial milestones; that Vaxart or its partners may experience manufacturing issues and delays due to events within, or outside of, Vaxart’s or its partners control, including the recent outbreak of COVID-19; difficulties in production, particularly in scaling up initial production, including difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel or key raw materials, and compliance with strictly enforced federal, state, and foreign regulations; that Operation Warp Speed may not result in a positive financial impact on Vaxart’s financial results that Vaxart may not be able to obtain, maintain and enforce necessary patent and other intellectual property protection; that Vaxart’s capital resources may be inadequate; Vaxart’s ability to resolve pending legal matters; Vaxart’s ability to obtain sufficient capital to fund its operations on terms acceptable to Vaxart, if at all; the impact of government healthcare proposals and policies; competitive factors; and other risks described in the “Risk Factors” sections of Vaxart’s Quarterly and Annual Reports filed with the SEC. Vaxart does not assume any obligation to update any forward-looking statements, except as required by law.
|Media Relations||Investor Relations|
Tel: (646) 970-4688
|David R. Holmes
LifeSci Advisors, LLC
Tel: (646) 970-4995